Immunotherapy of metastatic renal cell carcinoma (Q37463892)

20 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Immunotherapy of metastatic renal cell carcinoma (English)

1 reference

20 August 2017

1 reference

David F McDermott

1

1 reference

PubMed ID

19402060

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

2298-2305

1 reference

20 August 2017

10 Suppl

1 reference

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Immunotherapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcom

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24236

7 January 2021

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Interferon therapy for the treatment of renal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/CNCR.24236

Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/CNCR.24236

Identifiers

DOI

10.1002/CNCR.24236

1 reference

20 August 2017

1 reference

PubMed ID

19402060